サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1128179

スライド染色装置の世界市場：製品別 (試薬 (染色剤、プローブ、ABS)、装置 (自動、手動))・技術別 (H&E、IHC、ISH、細胞診)・用途別 (疾病診断 (がん)、研究)・エンドユーザー別 (病院、診断検査室)・地域別の将来予測 (2027年まで)

Slide Stainer Market by Product (Reagent (Stains, Probes, ABS), Equipment (Automated, Manual)), Technology (H&E, IHC, ISH, Cytology), Application (Disease Diagnosis (Cancer) Research), End User (Hospitals, Diagnostic Labs) - Global Forecast to 2027
出版日: | 発行: MarketsandMarkets | ページ情報: 英文 220 Pages | 納期: 即納可能 即納可能とは

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
スライド染色装置の世界市場：製品別 (試薬 (染色剤、プローブ、ABS)、装置 (自動、手動))・技術別 (H&E、IHC、ISH、細胞診)・用途別 (疾病診断 (がん)、研究)・エンドユーザー別 (病院、診断検査室)・地域別の将来予測 (2027年まで)
出版日: 2022年09月16日
発行: MarketsandMarkets
ページ情報: 英文 220 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

スライド染色装置の世界市場は、2022年に43億米ドル、2027年には59億米ドルに達し、2022年から2027年までのCAGRは6.8%と予測されています。

この市場の成長を促す主な要因は、がん診断件数の多さ、抗がん剤研究の増加、医療インフラの進歩、高齢者人口の拡大です。しかし、スライド染色装置の高コストとスライド染色システム市場の再編が、今後数年間、この市場の成長を抑制する要因になると予想されます。

"2021年には試薬・キット分野が最大のシェアを占める"

スライド染色装置市場を製品別に見ると、試薬・キットは、がんや感染症、その他の慢性疾患など様々な疾患の診断・研究において高い使用率を示しており、圧倒的なシェアを誇っています。肺病理関連の診断や研究関連では、スライド染色量が増加しています。

"2021年にはヘマトキシリン・エオシンのセグメントが最大のシェアを占める"

スライド染色装置市場を技術別に見ると、ヘマトキシリン・エオシン (H&E) が圧倒的に大きくなっています。H&Eは、がんや感染症、その他の慢性疾患の診断・研究に最も使用されるスライド染色法です。

"疾患診断のセグメントが、予測期間中に急速な成長を遂げる"

スライド染色装置市場を用途別に見ると、2021年には疾患診断アが最大のシェアを占め、最も高いCAGRで成長すると予測されます。各種がん (乳がん、胃がん、リンパ腫など) や感染症などの症例が増加していることなどが、この分野の成長率を押し上げています。

"エンドユーザー別では、病院・診断センターのセグメントが最大のシェアを占める"

スライド染色装置市場をエンドユーザー別に見ると、病院・診断センターセグメントが圧倒的なシェアを占めており、これはがん生検、診断、研究によるがんスライド染色量の多さが要因となっています。

"アジア太平洋：スライド染色装置で最も成長率の高い地域市場"

地域別に見ると、2021年には北米地域が市場を独占し、欧州がそれに続いています。他方、アジア太平洋では、医療インフラの改善、医療投資、高齢者の膨大な患者層、がん・感染症・その他の慢性合併症の症例の増加により、2022年から2027年の予測期間中に最も速い成長率で成長すると予想されます。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • イントロダクション
  • 市場力学
  • バリューチェーン分析
  • サプライチェーン分析
  • 技術分析
  • ポーターのファイブフォース分析
  • 主な利害関係者と購入基準
  • 規制状況
  • 特許分析
  • 主な会議とイベント (2022年～2023年)
  • 価格分析
  • 貿易分析
  • エコシステム分析
  • 顧客のビジネスに影響を与える動向/混乱

第6章 スライド染色装置市場：製品別

  • イントロダクション
  • 試薬・キット
    • 染色剤
    • ブロッキング用血清・試薬
    • 希釈剤・緩衝液
    • 封入剤・固定試薬・包埋剤
    • プローブ
    • 抗体
  • 装置
    • 自動・半自動スライド染色機
    • 手動スライド染色セット
  • 消耗品・アクセサリー

第7章 スライド染色装置市場：用途別

  • イントロダクション
  • 疾患診断
    • 乳がん
    • 胃がん
    • リンパ腫
    • 前立腺がん
    • 非小細胞肺がん
    • その他の疾患
  • 医学研究

第8章 スライド染色装置市場：技術別

  • イントロダクション
  • ヘマトキシリン・エオシン (H&E)
  • 免疫組織化学 (IHC)
  • in situ ハイブリダイゼーション (ISH)
  • 細胞診
  • 微生物学
  • 血液学
  • 特殊染色

第9章 スライド染色装置市場：エンドユーザー別

  • イントロダクション
  • 病院・診断検査室
  • 教育・研究機関
  • 製薬・バイオテクノロジー企業
  • その他のエンドユーザー

第10章 スライド染色装置市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • 他の欧州諸国
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 他のアジア太平洋諸国
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 主要企業の戦略/有力企業
  • 収益シェア分析
  • 市場シェア分析
  • 企業評価マトリックス
  • 中小企業/新興企業向けの企業評価マトリックス
  • 企業のフットプリント分析
    • 企業の地域フットプリント
    • 企業の製品フットプリント
    • 企業の全体的なフットプリント
  • 競合ベンチマーキング
  • 競合シナリオ
    • 製品の発売/承認
    • 資本取引
    • その他の動向

第12章 企業プロファイル

  • 主要企業
    • F. HOFFMANN-LA ROCHE LTD.
    • DANAHER
    • PHC HOLDINGS CORPORATION
    • MERCK KGAA
    • AGILENT TECHNOLOGIES, INC.
    • ABCAM PLC.
    • BECTON, DICKINSON AND COMPANY
    • SIEMENS HEALTHINEERS AG
    • SAKURA FINETEK JAPAN CO., LTD.
    • BIOCARE MEDICAL, LLC
    • HARDY DIAGNOSTICS
    • GENERAL DATA COMPANY, INC.
    • ELITECHGROUP
    • BIOGENEX
    • HISTO-LINE LABORATORIES
    • SLEE MEDICAL GMBH
    • AMOS SCIENTIFIC PTY LTD.
  • その他の企業
    • MEDITE MEDICAL GMBH
    • CELLPATH LTD.
    • DIAPATH S.P.A.
    • BIO SB, INC.
    • ROCKLAND IMMUNOCHEMICALS, INC.
    • CELL SIGNALING TECHNOLOGY, INC.
    • DIAGNOSTIC BIOSYSTEMS, INC.
    • DAKEWE BIOTECHNOLOGY CO., LTD.
    • THERMO FISHER SCIENTIFIC, INC.

第13章 付録

目次
Product Code: AST 6418

The global slide stainer market is valued at USD 4.3 billion in 2022 and is projected to reach USD 5.9 billion in 2027 at a CAGR of 6.8% from 2022 to 2027. The major factors driving the growth of this market are the high volume of cancer diagnoses, increasing cancer drug research, advancing healthcare infrastructure and expanding geriatric population. However, the high cost of the slide staining systems and the consolidation in the slide stainer system market are factors expected to restrain the growth of this market in the coming years.

"The reagents & kits segment accounted for the largest share of the slide stainer market in 2021."

The slide stainer market by product is further segmented into the slide stainer market is segmented into reagents & kits, equipment, and consumables & accessories. The reagents & kits dominated the slide stainer products with the high usage of the reagent & kits in the diagnosis and research of various diseases such as cancer, infections and other chronic conditions. The lung pathology-related diagnosis and research-related studies have increased the volume of slide staining.

"The hematoxyline & eosin segment accounted for the largest share of the slide stainer market in 2021."

The slide stainer market by technology is further segmented into the slide stainer market is segmented into hematoxylin & eosin, immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special staining. The hematoxylin & eosin dominated the slide stainer products. Hematoxylin & eosin is the most used slide staining technique used for the diagnosis and research of cancer, infectious, and other chronic diseases.

"The disease diagnosis application segment is estimated to grow at a rapid rate during the forecast period."

Based on application, the slide stainer market is segmented into disease diagnosis and medical research. In 2021, the disease diagnosis application accounted for the largest share of the slide stainer market and is projected to grow at the highest CAGR. The increasing cases of cancer, such as breast cancer, gastric cancer, lymphoma, etc., and infections. The prevalence of cancer and various infections is rising, which has boosted the growth rate of the application segment.

"Hospitals & diagnostics centers segment accounted for the largest share of end users of the slide stainer market in 2021."

The end user segment of the slide stainer market is further segmented into hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies, and other end users. The dominant share was accounted for by the hospitals and diagnostics centers segment in 2021, which was driven by the high volume of cancer slide staining due to the cancer biopsies, diagnosis and research. Also, the high burden of infections such as COVID-19 and their diagnosis have promoted the segment of the slide stainer end users.

"Asia Pacific is the fastest-growing regional market for slide stainer."

In 2021, the slide stainer market was further divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America region ruled the market in 2021, followed by Europe. Although, the Asia Pacific region is expected to grow with the fastest growth rate during the forecast period of 2022 to 2027, with the improving healthcare infrastructure, medical investments, vast patient base of geriatric patients and increasing cases of cancer, infections and other chronic complications.

The breakdown of the primary participants' profiles has been provided below:

  • By Company Type: Tier 1: 31%, Tier 2: 46%, and Tier 3: 23%
  • By Designation: C-level: 42%, Director-level: 26%, and Others: 32%
  • By Region: North America: 35%, Europe: 30%, Asia Pacific: 21%, and Rest of the World: 14%

The key players operating in the slide stainer market include the following:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Danaher Corporation (US)
  • PHC Holdings Corporation (Japan)
  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGAA (Germany)
  • Agilent Technologies, Inc. (US)
  • Abcam Plc. (UK)
  • Becton, Dickinson and Company (US)
  • Siemens Healthineers AG (Germany)
  • Biocare Medical, LLC (US)
  • Hardy Diagnostics (US)
  • General Data Company (US)
  • ELITechGroup (France)
  • Biogenex (US)
  • Histo-Line Laboratories (Italy)
  • SLEE MEDICAL GmbH (Germany)
  • Amos scientific Pty Ltd. (Australia)
  • MEDITE Medical GMBH (Germany)
  • Cellpath Ltd (UK)
  • Diapath S.P.A. (Italy)
  • Bio SB, Inc. (US)
  • Rockland Immunochemicals, Inc. (US)
  • Cell Signaling Technology, Inc. (US)
  • Diagnostic BioSystems, Inc. (US)
  • Dakewe Biotech Co., Ltd. (China)

Research Coverage

This report studies the slide stainer market based on product, application, technology, end user and region. The report also analyzes factors (drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total slide stainer market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the slide stainer offered by the top 17 players in the market. The report analyzes the slide stainer market by product and region.
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various slide stainers across key geographic regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the slide stainer market.
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the slide stainer market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS AND EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 GEOGRAPHIC SCOPE
    • 1.3.2 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 MARKET STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Secondary sources
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Key industry insights
      • 2.1.2.3 Breakdown of primary interviews
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: F. HOFFMANN-LA ROCHE AG
    • FIGURE 6 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
    • 2.2.1 GROWTH FORECAST
    • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • FIGURE 8 TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 9 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 INDICATORS AND ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
    • TABLE 1 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

    • FIGURE 10 SLIDE STAINER MARKET, BY PRODUCT, 2022 VS. 2027 (USD BILLION)
    • FIGURE 11 SLIDE STAINER MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD BILLION)
    • FIGURE 12 SLIDE STAINER MARKET, BY APPLICATION, 2022 VS. 2027 (USD BILLION)
    • FIGURE 13 SLIDE STAINER MARKET, BY END USER, 2022 VS. 2027 (USD BILLION)
    • FIGURE 14 GEOGRAPHIC SNAPSHOT: SLIDE STAINER MARKET

4 PREMIUM INSIGHTS

  • 4.1 SLIDE STAINER MARKET OVERVIEW
    • FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
  • 4.2 ASIA PACIFIC SLIDE STAINER MARKET: BY APPLICATION AND COUNTRY (2021)
    • FIGURE 16 DISEASE DIAGNOSTICS SEGMENT DOMINATED ASIA PACIFIC SLIDE STAINER MARKET, BY APPLICATION, IN 2021
  • 4.3 GEOGRAPHIC MIX: SLIDE STAINER MARKET
    • FIGURE 17 NORTH AMERICA TO DOMINATE SLIDE STAINER MARKET DURING FORECAST PERIOD
  • 4.4 SLIDE STAINER MARKET: GEOGRAPHIC SNAPSHOT
    • FIGURE 18 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 SLIDE STAINER MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising prevalence of cancer
    • TABLE 2 INCREASING INCIDENCE OF CANCER, BY REGION, 2020 VS. 2030 VS. 2040 (MILLION)
    • TABLE 3 PROJECTED INCREASE IN GLOBAL NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035
      • 5.2.1.2 Recommendations for cancer screening
      • 5.2.1.3 Increasing healthcare expenditure
    • FIGURE 20 HEALTH EXPENDITURE PER CAPITA, 2010-2019
    • FIGURE 21 HEALTH EXPENDITURE (% OF GDP), 2010-2019
      • 5.2.1.4 Rising geriatric population and subsequent growth in chronic and infectious disease prevalence
    • FIGURE 22 ESTIMATED INCREASE IN CANCER INCIDENCE (MILLION), 2020 VS. 2030
    • FIGURE 23 ESTIMATED CANCER DEATHS (MILLION), 2020 VS. 2030
      • 5.2.1.5 Growing number of private diagnostic centers globally
      • 5.2.1.6 Increasing automation in laboratories
      • 5.2.1.7 Increasing use of AI in histopathology
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High equipment cost
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 High-growth opportunities in emerging markets
    • FIGURE 24 GROWTH IN HEALTHCARE EXPENDITURE PER CAPITA IN BRICS COUNTRIES, 2012-2019
      • 5.2.3.2 Increasing number of clinical trials pertaining to cancer drugs
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Dearth of knowledgeable and skilled technicians
    • TABLE 4 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018
      • 5.2.4.2 Product recalls
    • TABLE 5 INDICATIVE LIST OF PRODUCT RECALLS FOR SLIDE STAINING EQUIPMENT (2019-2022)
      • 5.2.4.3 Availability of refurbished equipment
  • 5.3 VALUE CHAIN ANALYSIS
    • FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.4 SUPPLY CHAIN ANALYSIS
    • FIGURE 26 DIRECT DISTRIBUTION-PREFERRED STRATEGY FOR PROMINENT COMPANIES
  • 5.5 TECHNOLOGY ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 THREAT OF NEW ENTRANTS
    • 5.6.2 INTENSITY OF COMPETITIVE RIVALRY
    • 5.6.3 BARGAINING POWER OF BUYERS
    • 5.6.4 BARGAINING POWER OF SUPPLIERS
    • 5.6.5 THREAT OF SUBSTITUTES
  • 5.7 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 27 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS
    • TABLE 6 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR TOP 3 END USERS (%)
    • 5.7.2 BUYING CRITERIA
    • FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS
    • TABLE 7 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • 5.8 REGULATORY LANDSCAPE
    • TABLE 8 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING SLIDE STAINING MARKET
  • 5.9 PATENT ANALYSIS
  • 5.10 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 9 LIST OF CONFERENCES AND EVENTS
  • 5.11 PRICING ANALYSIS
    • TABLE 10 PRICE RANGE FOR SLIDE STAINERS
  • 5.12 TRADE ANALYSIS
    • TABLE 11 IMPORT DATA FOR HS CODE 847989, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 12 EXPORT DATA FOR HS CODE 847989, BY COUNTRY, 2017-2021 (USD MILLION)
  • 5.13 ECOSYSTEM ANALYSIS
    • TABLE 13 ROLE IN ECOSYSTEM
    • FIGURE 29 KEY PLAYERS OPERATING IN SLIDE STAINER MARKET
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

6 SLIDE STAINER MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
    • TABLE 14 SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
  • 6.2 REAGENTS AND KITS
    • TABLE 15 SLIDE STAINER MARKET FOR REAGENTS AND KITS, BY TYPE, 2020-2027 (USD MILLION)
    • 6.2.1 STAINS
      • 6.2.1.1 Staining is extensively used in diagnosis and research of carcinoma tissue samples
    • TABLE 16 SLIDE STAINER MARKET FOR STAINS, BY REGION, 2020-2027 (USD MILLION)
    • 6.2.2 BLOCKING SERA AND REAGENTS
      • 6.2.2.1 Blocking sera and reagents prevent nonspecific binding and reduce background noise
    • TABLE 17 SLIDE STAINER MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2020-2027 (USD MILLION)
    • 6.2.3 DILUENTS AND BUFFERS
      • 6.2.3.1 Diluents and buffers are used for IHC workflow optimization
    • TABLE 18 SLIDE STAINER MARKET FOR DILUENTS AND BUFFERS, BY REGION, 2020-2027 (USD MILLION)
    • 6.2.4 MOUNTING MEDIA, FIXATIVE REAGENTS, AND EMBEDDING MEDIA
      • 6.2.4.1 Fixative reagents are used to immobilize antigens and retain cellular and subcellular structures
    • TABLE 19 SLIDE STAINER MARKET FOR MOUNTING MEDIA, FIXATIVE REAGENTS, AND EMBEDDING MEDIA, BY REGION, 2020-2027 (USD MILLION)
    • 6.2.5 PROBES
      • 6.2.5.1 Probes are widely used in ISH
    • TABLE 20 SLIDE STAINER MARKET FOR PROBES, BY REGION, 2020-2027 (USD MILLION)
    • 6.2.6 ANTIBODIES
      • 6.2.6.1 Increasing prevalence of infectious diseases and cancer to drive segment growth
    • TABLE 21 SLIDE STAINER MARKET FOR ANTIBODIES, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 EQUIPMENT
    • TABLE 22 SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • 6.3.1 AUTOMATED AND SEMI-AUTOMATED SLIDE STAINERS
      • 6.3.1.1 High-throughput efficacy and accuracy of staining biological samples driving segment growth
    • TABLE 23 KEY BRANDS OF AUTOMATED SLIDE STAINERS
    • TABLE 24 AUTOMATED AND SEMI-AUTOMATED SLIDE STAINERS MARKET, BY REGION, 2020-2027 (USD MILLION)
    • 6.3.2 MANUAL SLIDE STAINING SETS
      • 6.3.2.1 Low cost of manual staining sets to drive segment growth
    • TABLE 25 KEY BRANDS OF MANUAL SLIDE STAINING SETS
    • TABLE 26 MANUAL SLIDE STAINERS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 CONSUMABLES AND ACCESSORIES
    • TABLE 27 SLIDE STAINER MARKET FOR CONSUMABLES AND ACCESSORIES, BY REGION, 2020-2027 (USD MILLION)

7 SLIDE STAINER MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • TABLE 28 SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 7.2 DISEASE DIAGNOSTICS
    • TABLE 29 SLIDE STAINER MARKET FOR DISEASE DIAGNOSTICS, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • 7.2.1 BREAST CANCER
      • 7.2.1.1 High prevalence of breast cancer to drive segment growth
    • TABLE 30 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 31 SLIDE STAINER MARKET FOR BREAST CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.2 GASTRIC CANCER
      • 7.2.2.1 Growing prevalence of and increasing research on gastric cancer to drive segment growth
    • TABLE 32 COLORECTAL CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 33 SLIDE STRAINER MARKET FOR GASTRIC CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.3 LYMPHOMA
      • 7.2.3.1 IHC and biopsy are preferable tests to diagnose lymphoma
    • TABLE 34 HODGKIN'S LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
    • TABLE 35 NON-HODGKIN'S LYMPHOMA INCIDENCE, BY REGION, 2018 VS. 2025
    • TABLE 36 SLIDE STAINER MARKET FOR LYMPHOMA, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.4 PROSTATE CANCER
      • 7.2.4.1 IHC tests are used to identify prostate cancer
    • TABLE 37 PROSTATE CANCER INCIDENCE, BY REGION, 2018 VS. 2025
    • TABLE 38 SLIDE STAINER MARKET FOR PROSTATE CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.5 NON-SMALL CELL LUNG CANCER
      • 7.2.5.1 IHC helps analyze adenocarcinoma and squamous carcinoma of lungs through staining of antibodies
    • TABLE 39 NON-SMALL CELL LUNG CANCER INCIDENCE, BY REGION, 2020 VS. 2040
    • TABLE 40 SLIDE STAINER MARKET FOR NON-SMALL CELL LUNG CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 7.2.6 OTHER DISEASES
    • TABLE 41 SLIDE STAINER MARKET FOR OTHER DISEASES, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 MEDICAL RESEARCH
    • 7.3.1 WIDE USE OF TISSUE BIOPSY AND SLIDE STAINING IN DRUG DEVELOPMENT TO DRIVE SEGMENT GROWTH
    • TABLE 42 SLIDE STAINER MARKET FOR MEDICAL RESEARCH, BY REGION, 2020-2027 (USD MILLION)

8 SLIDE STAINER MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 43 SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 8.2 HEMATOXYLIN & EOSIN (H&E)
    • 8.2.1 WIDE USE OF H&E FOR STAINING VARIOUS BIOLOGICAL SAMPLES DRIVING SEGMENT GROWTH
    • TABLE 44 HEMATOXYLIN & EOSIN SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 IMMUNOHISTOCHEMISTRY (IHC)
    • 8.3.1 AUTOMATION OF IHC TECHNIQUES DRIVING SEGMENT GROWTH
    • TABLE 45 IMMUNOHISTOCHEMISTRY SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.4 IN SITU HYBRIDIZATION (ISH)
    • 8.4.1 EMERGING ISH STAINING TECHNIQUES SUCH AS FISH AND CISH DRIVING SEGMENT GROWTH
    • TABLE 46 IN SITU HYBRIDIZATION SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.5 CYTOLOGY
    • 8.5.1 WIDE USE OF CYTOLOGY FOR CANCER STUDIES DRIVING SEGMENT GROWTH
    • TABLE 47 CYTOLOGY SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.6 MICROBIOLOGY
    • 8.6.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES DRIVING SEGMENT GROWTH
    • TABLE 48 GLOBALLY REPORTED CASES OF INFECTIOUS DISEASES
    • TABLE 49 MICROBIOLOGY SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.7 HEMATOLOGY
    • 8.7.1 INCREASING PREVALENCE OF HEMATOLOGY DISORDERS DRIVING SEGMENT GROWTH
    • TABLE 50 HEMATOLOGY SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 8.8 SPECIAL STAINING
    • 8.8.1 SPECIAL STAINING IS USED WHERE ROUTINE H&E TECHNIQUES CANNOT PROVIDE NEEDED INFORMATION
    • TABLE 51 SPECIAL SLIDE STAINERS OFFERED BY SOME PLAYERS
    • TABLE 52 SPECIAL SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)

9 SLIDE STAINER MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 53 SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES
    • 9.2.1 NUMBER OF HOSPITALS AND DIAGNOSTIC LABORATORIES INCREASING IN SEVERAL COUNTRIES
    • TABLE 54 SLIDE STAINER MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 ACADEMIC AND RESEARCH INSTITUTES
    • 9.3.1 INCREASING INVESTMENTS FOR RESEARCH ON DISEASE DIAGNOSIS DRIVING SEGMENT GROWTH
    • TABLE 55 SLIDE STAINER MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)
  • 9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
    • 9.4.1 INCREASING RESEARCH ON DRUG DISCOVERY TO DRIVE SEGMENT GROWTH
    • TABLE 56 SLIDE STAINER MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 57 ONCOLOGY CONTRACT RESEARCH ORGANIZATIONS
    • TABLE 58 SLIDE STAINER MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

10 SLIDE STAINER MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 59 SLIDE STAINER MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 30 NORTH AMERICA: CANCER INCIDENCE AND MORTALITY, 2012-2035
    • FIGURE 31 NORTH AMERICA: SLIDE STAINER MARKET SNAPSHOT
    • TABLE 60 NORTH AMERICA: SLIDE STAINER MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 61 NORTH AMERICA: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 62 NORTH AMERICA: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 63 NORTH AMERICA: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 64 NORTH AMERICA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 65 NORTH AMERICA: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 66 NORTH AMERICA: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 67 NORTH AMERICA: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 US to dominate global slide stainer market
    • TABLE 68 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 69 US: KEY MACROINDICATORS
    • TABLE 70 US: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 71 US: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 72 US: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 73 US: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing prevalence of cancer to drive market growth
    • TABLE 74 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
    • TABLE 75 CANADA: KEY MACROINDICATORS
    • TABLE 76 CANADA: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 77 CANADA: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 78 CANADA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 79 CANADA: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 32 EUROPE: CANCER INCIDENCE AND MORTALITY, 2012-2035
    • TABLE 80 EUROPE: SLIDE STAINER MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 81 EUROPE: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 82 EUROPE: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 83 EUROPE: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 84 EUROPE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 85 EUROPE: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 86 EUROPE: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 87 EUROPE: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Increasing cancer screening initiatives to drive market growth
    • TABLE 88 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
    • TABLE 89 GERMANY: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 90 GERMANY: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 91 GERMANY: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 92 GERMANY: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.2 FRANCE
      • 10.3.2.1 Government funding for cancer diagnosis and prevention to support market growth
    • TABLE 93 FRANCE: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 94 FRANCE: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 95 FRANCE: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 96 FRANCE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 97 FRANCE: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Government initiatives to drive market growth
    • TABLE 98 UK: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 99 UK: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 100 UK: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 101 UK: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 High incidence of cancer to support market growth
    • TABLE 102 ITALY: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
    • TABLE 103 ITALY: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 104 ITALY: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 105 ITALY: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 106 ITALY: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 High incidence of chronic diseases to drive market growth
    • TABLE 107 SPAIN: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
    • TABLE 108 SPAIN: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 109 SPAIN: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 110 SPAIN: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 111 SPAIN: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 112 LUNG CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
    • TABLE 113 LIVER CANCER INCIDENCE IN KEY REST OF EUROPE COUNTRIES, 2020 VS. 2040
    • TABLE 114 ROE: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 115 ROE: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 116 ROE: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 117 ROE: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 33 ASIA PACIFIC: CANCER INCIDENCE AND MORTALITY, 2012-2035
    • FIGURE 34 ASIA PACIFIC: SLIDE STAINER MARKET SNAPSHOT
    • TABLE 118 APAC: SLIDE STAINER MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 119 APAC: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 120 APAC: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 121 APAC: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 122 APAC: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 123 APAC: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 124 APAC: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 125 APAC: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.1 JAPAN
      • 10.4.1.1 Advanced healthcare infrastructure to support market growth
    • TABLE 126 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 127 JAPAN: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 128 JAPAN: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 129 JAPAN: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 130 JAPAN: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.2 CHINA
      • 10.4.2.1 Increasing healthcare expenditure and funding to drive market growth
    • TABLE 131 CHINA: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 132 CHINA: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 133 CHINA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 134 CHINA: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Expanding healthcare sector to drive market growth
    • TABLE 135 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
    • TABLE 136 INDIA: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 137 INDIA: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 138 INDIA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 139 INDIA: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 10.4.4 REST OF ASIA PACIFIC
    • TABLE 140 INCIDENCE OF CANCER IN REST OF ASIA PACIFIC
    • TABLE 141 ROAPAC: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 142 ROAPAC: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 143 ROAPAC: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 144 ROAPAC: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 INCREASING NUMBER OF CANCER SCREENING PROGRAMS TO SUPPORT MARKET GROWTH
    • TABLE 145 LUNG CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
    • TABLE 146 LIVER CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
    • TABLE 147 BREAST CANCER INCIDENCE IN KEY LATIN AMERICAN COUNTRIES, 2018 VS. 2025
    • TABLE 148 LATAM: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 149 LATAM: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 150 LATAM: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 151 LATAM: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 152 LATAM: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 153 LATAM: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 154 LATAM: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 10.6 MIDDLE EAST AND AFRICA
    • 10.6.1 INCREASING INCIDENCE OF CANCER IN AFRICA TO SUPPORT MARKET GROWTH
    • TABLE 155 AFRICA: CANCER INCIDENCE, BY TYPE OF CANCER, 2018 VS. 2025
    • TABLE 156 MEA: SLIDE STAINER MARKET, BY PRODUCT, 2020-2027 (USD MILLION)
    • TABLE 157 MEA: SLIDE STAINER REAGENTS AND KITS MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 158 MEA: SLIDE STAINER EQUIPMENT MARKET, BY TYPE, 2020-2027 (USD MILLION)
    • TABLE 159 MEA: SLIDE STAINER MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 160 MEA: SLIDE STAINER MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 161 MEA: SLIDE STAINER MARKET, BY DISEASE TYPE, 2020-2027 (USD MILLION)
    • TABLE 162 MEA: SLIDE STAINER MARKET, BY END USER, 2020-2027 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • TABLE 163 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SLIDE STAINER MARKET
  • 11.3 REVENUE SHARE ANALYSIS
    • FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN SLIDE STAINER MARKET
  • 11.4 MARKET SHARE ANALYSIS
    • TABLE 164 SLIDE STAINER MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX
    • 11.5.1 STARS
    • 11.5.2 PERVASIVE PLAYERS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PARTICIPANTS
    • FIGURE 36 SLIDE STAINER MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS
  • 11.6 COMPANY EVALUATION MATRIX FOR SMES/START-UPS
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 STARTING BLOCKS
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 37 SLIDE STAINER MARKET: COMPANY EVALUATION MATRIX FOR SMES/ START-UPS
  • 11.7 COMPANY FOOTPRINT ANALYSIS
    • 11.7.1 REGIONAL FOOTPRINT OF COMPANIES
    • 11.7.2 PRODUCT FOOTPRINT OF COMPANIES
    • 11.7.3 OVERALL FOOTPRINT OF COMPANIES
  • 11.8 COMPETITIVE BENCHMARKING
    • TABLE 165 SLIDE STAINER MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES/APPROVALS
    • TABLE 166 KEY PRODUCT LAUNCHES
    • 11.9.2 DEALS
    • TABLE 167 KEY DEALS
    • 11.9.3 OTHER DEVELOPMENTS
    • TABLE 168 OTHER KEY DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
  • (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
    • 12.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 169 F. HOFFMAN-LA ROCHE LTD.: BUSINESS OVERVIEW
    • FIGURE 38 F. HOFFMAN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
    • 12.1.2 DANAHER
    • TABLE 170 DANAHER: BUSINESS OVERVIEW
    • FIGURE 39 DANAHER: COMPANY SNAPSHOT (2021)
    • 12.1.3 PHC HOLDINGS CORPORATION
    • TABLE 171 PHC HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 40 PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT (2021)
    • 12.1.4 MERCK KGAA
    • TABLE 172 MERCK KGAA: BUSINESS OVERVIEW
    • FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2021)
    • 12.1.5 AGILENT TECHNOLOGIES, INC.
    • TABLE 173 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
    • 12.1.6 ABCAM PLC.
    • TABLE 174 ABCAM PLC.: BUSINESS OVERVIEW
    • FIGURE 43 ABCAM PLC.: COMPANY SNAPSHOT (2021)
    • 12.1.7 BECTON, DICKINSON AND COMPANY
    • TABLE 175 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
    • FIGURE 44 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
    • 12.1.8 SIEMENS HEALTHINEERS AG
    • TABLE 176 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
    • FIGURE 45 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
    • 12.1.9 SAKURA FINETEK JAPAN CO., LTD.
    • TABLE 177 SAKURA FINETEK JAPAN CO., LTD.: BUSINESS OVERVIEW
    • 12.1.10 BIOCARE MEDICAL, LLC
    • TABLE 178 BIOCARE MEDICAL, LLC.: BUSINESS OVERVIEW
    • 12.1.11 HARDY DIAGNOSTICS
    • TABLE 179 HARDY DIAGNOSTICS: BUSINESS OVERVIEW
    • 12.1.12 GENERAL DATA COMPANY, INC.
    • TABLE 180 GENERAL DATA COMPANY, INC.: BUSINESS OVERVIEW
    • 12.1.13 ELITECHGROUP
    • TABLE 181 ELITECHGROUP: BUSINESS OVERVIEW
    • 12.1.14 BIOGENEX
    • TABLE 182 BIOGENEX.: BUSINESS OVERVIEW
    • 12.1.15 HISTO-LINE LABORATORIES
    • TABLE 183 HISTO-LINE LABORATORIES: BUSINESS OVERVIEW
    • 12.1.16 SLEE MEDICAL GMBH
    • TABLE 184 SLEE MEDICAL GMBH: BUSINESS OVERVIEW
    • 12.1.17 AMOS SCIENTIFIC PTY LTD.
    • TABLE 185 AMOS SCIENTIFIC PTY LTD.: BUSINESS OVERVIEW
  • *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 MEDITE MEDICAL GMBH
    • TABLE 186 MEDITE MEDICAL GMBH: COMPANY OVERVIEW
    • 12.2.2 CELLPATH LTD.
    • TABLE 187 CELLPATH LTD.: COMPANY OVERVIEW
    • 12.2.3 DIAPATH S.P.A.
    • TABLE 188 DIAPATH S.P.A.: COMPANY OVERVIEW
    • 12.2.4 BIO SB, INC.
    • TABLE 189 BIO SB, INC.: COMPANY OVERVIEW
    • 12.2.5 ROCKLAND IMMUNOCHEMICALS, INC.
    • TABLE 190 ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW
    • 12.2.6 CELL SIGNALING TECHNOLOGY, INC.
    • TABLE 191 CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW
    • 12.2.7 DIAGNOSTIC BIOSYSTEMS, INC.
    • TABLE 192 DIAGNOSTIC BIOSYSTEMS, INC.: COMPANY OVERVIEW
    • 12.2.8 DAKEWE BIOTECHNOLOGY CO., LTD.
    • TABLE 193 DAKEWE BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
    • 12.2.9 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 194 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS